Oral Asciminib in CML

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

5 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called asciminib. The overall goal of the study is to find out how safe and effective the study drug is in treating people that have been diagnosed with Chronic Myeloid Leukemia (CML) and have not responded to treatment.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT04925479

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
24-021950
Official Title:
A Multi-Center, Open-Label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients with Ph+ CML in Chronic Phase, Previously Treated with One or More TKI
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 17 Years
Gender:
All
Study Categories:

Visit Criteria

The study will enroll patients between 1 and less than 18 years of age that have been diagnosed with Chronic Myeloid Leukemia (CML) and have not responded to treatment. Participants in this research will:

  • Receive a study drug called asciminib
  • Have research blood tests
  • Have dual-energy x-ray absorptiometry (DEXA) scans
  • Have electrocardiograms (ECGs)
  • Have echocardiograms (ECHOs)
  • Complete questionnaires
Leader
Sarah K. Tasian

Sarah Tasian, MD